Colorectal Cancer Incidence in Lynch Syndrome Patients: First Report of a Multicenter Nation-Wide Study

Sánchez, Ariadna; Navarro, Matilde; Ocaña, Teresa; Pineda, Marta; Rodríguez-Moranta, Francisco; Soriano, Antonio; Cajal, Teresa Ramón y; Llort, Gemma; Yagüe, Carme; Picó, María Dolores; Jover, Rodrigo; Fernandez, Adrià Lopez; Castro, Eva Martínez de; Alvarez, Cristina; Bessa, Xavier; Rivas, Laura; Rodríguez‐Alcalde, Daniel; Dacal, Andrés; Herraiz, Maite; Garau, Catalina; Bujanda, Luís; Cid, Lucía; Povés, Carmen; Garzon, Marta; Pizarro, Ángeles; Gómez, Antonio; Salces, Inmaculada; Ponce, Marta; Carrillo-Palau, Marta; Aguirre, Elena; Saperas, Enric; Marnrique, Anna Virgili; Masferrer, David Fisas; Piñol, Virgı́nia; Carballal, Sabela; Rivero, Liseth; Pellisé, María; Serra, Miquel; Balmaña, J.; Capellà, Gabriel; Brunet, Joan; Castells, Antoni; Moreira, Leticia; Balaguer, Francesc

doi:10.1016/s0016-5085(17)32003-6

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies confirmed that the age of CRC onset in carriers of pathogenic variants of the MSH6 and PMS2 genes was delayed by 10 years compared to carriers of MLH1 and MSH2 pathogenic variants [52,53], with very low CRC risk before the age of 30 years [51,52]. Similarly, there was an extremely low risk of developing advanced adenoma (mean number of neoplastic lesions for ages 20 -29 years, 1.3 ± 0.5) or CRC (1 % in 5 years) before the age of 30 for carriers of pathogenic variants of the MLH1 and MSH2 genes [52,53], with very high numbers needed to screen to prevent one CRC death [54]. It is important to take into consideration that, to prevent ascertainment bias, index cases are not included in the retrospective and prospective cohort studies.…”

Section: Colonoscopy Surveillance: Starting Agementioning

confidence: 88%

Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

et al. 2019

Self Cite

View full text Add to dashboard Cite

Main RecommendationsESGE recommends that individuals with Lynch syndrome should be followed in dedicated units that practice monitoring of compliance and endoscopic performance measures.Strong recommendation, low quality evidence, level of agreement 100 %.ESGE recommends starting colonoscopy surveillance at the age of 25 years for MLH1 and MSH2 mutation carriers and at the age of 35 years for MSH6 and PMS2 mutation carriers.Strong recommendation, moderate quality evidence, level of agreement 100 %. ESGE recommends the routine use of high-definition endoscopy systems in individuals with Lynch syndrome. Strong recommendation, high quality evidence, level of agreement 100 %. ESGE suggests the use of chromoendoscopy may be of benefit in individuals with Lynch syndrome undergoing colonoscopy; however routine use must be balanced against costs, training, and practical considerations.Weak recommendation, moderate quality evidence, level of agreement 89 %.ESGE recommends definition of familial risk of colorectal cancer as the presence of at least two first-degree relatives with colorectal cancer or at least one first-degree relative with colorectal cancer before the age of 50 years.Strong recommendation, moderate quality evidence, level of agreement 92 %.ESGE recommends colonoscopy surveillance in first-degree relatives of colorectal cancer patients in families that fulfill the definition of familial risk of colorectal cancer.Strong recommendation, moderate quality evidence, level of agreement 100 %.

show abstract

Section: Colonoscopy Surveillance: Starting Agementioning

confidence: 88%

Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

Recent advances in Lynch syndrome

2019

View full text Add to dashboard Cite

Lynch syndrome is one of the most common hereditary cancer predisposition syndromes and is associated with increased risks of colorectal and endometrial cancer, as well as multiple other cancer types. While the mechanism of mismatch repair deficiency and microsatellite instability and its role in Lynch-associated carcinogenesis has been known for some time, there have been significant advances recently in diagnostic testing and the understanding of the molecular pathogenesis of Lynch tumors. There is also an increased awareness that the clinical phenotype and cancer risk varies by specific mismatch repair mutation, which in turn has implications on surveillance strategies for patients. Even the treatment of Lynch-associated cancers has changed with the addition of immunotherapy for advanced disease. This progress report aims to review some of the many advances in epidemiology, molecular pathogenesis, diagnosis, clinical phenotype, cancer surveillance, treatment, and chemo-and immune-prevention strategies in the Lynch syndrome field over the past five years.

show abstract

Letter to the Editor-Recent advances in Lynch syndrome: response to Møller et al.

2020

View full text Add to dashboard Cite

Colorectal Cancer Incidence in Lynch Syndrome Patients: First Report of a Multicenter Nation-Wide Study

Cited by 3 publications

References 0 publications

Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Recent advances in Lynch syndrome

Letter to the Editor-Recent advances in Lynch syndrome: response to Møller et al.

Contact Info

Product

Resources

About